

## Gamaleya Center develops Delta and Omicron-adapted Sputnik V vaccine

23 August 2022 | News

**The new version is also addressing the L-452-R mutation in Omicron BA5 variant which was not present in the BA1 variant**



The Gamaleya National Research Center of Epidemiology and Microbiology (Gamaleya Center) and the Russian Direct Investment Fund (RDIF) have announced the development of the Sputnik V vaccine specifically adapted against Delta and Omicron variants of coronavirus.

The new version of Sputnik V has been Delta- and Omicron-adapted as Omicron is currently the dominant variant around the globe. This new version is also addressing the L-452-R mutation in Omicron BA5 variant which was not present in the BA1 variant.

The Delta and Omicron-adapted version of Sputnik V is the most promising version of the vaccine specifically adapted to new variants as compared to those tailored against the combination of the original strain and Omicron variant.

The Sputnik V vaccine adapted against the Delta and Omicron variants provides for a significant reduction in the viral load in the lungs of animals infected with the Omicron BA5 variant.